- Adial Pharmaceuticals granted restricted stock awards on April 7, 2026, covering 37,985 shares to CEO Cary Claiborne.
- CFO Vinay Shah received 17,325 restricted shares.
- COO Tony Goodman received 26,510 restricted shares.
- Restricted shares vest in full on earlier of one-year anniversary of grant date or change of control.
- Director compensation included 9,185 restricted shares each for Kevin Schuyler, Robertson H. Gilliland; Kermit Anderson received options for 9,185 shares at USD 1.64 exercise price.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-042057), on April 09, 2026, and is solely responsible for the information contained therein.
Comments